Catehol-o-methyltransferase gene Val158met polymorphism as a potential predictor of response to computer-assisted delivery of cognitive-behavioral therapy among cocaine-dependent individuals: Preliminary findings from a randomized controlled trial

American Journal on Addictions

Volumn 24, Issue 5, 2015, Pages 443-451

  Carroll, Kathleen M ^a   Herman, Aryeh ^a   Devito, Elise E ^a   Frankforter, Tami L ^a   Potenza, Marc N ^a   Sofuoglu, Mehmet ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CATECHOL METHYLTRANSFERASE; COCAINE; METHADONE; COMT PROTEIN, HUMAN; METHIONINE; VALINE;

ABSTINENCE; ADDICTION SEVERITY INDEX; ADULT; ARTICLE; ATTENTIONAL BIAS; COCAINE DEPENDENCE; COGNITION; COGNITIVE THERAPY; COMPUTER ASSISTED THERAPY; CONTROLLED STUDY; FEMALE; FOLLOW UP; GENE INTERACTION; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; METHADONE TREATMENT; RANDOMIZED CONTROLLED TRIAL; SELF REPORT; SINGLE NUCLEOTIDE POLYMORPHISM; TASK PERFORMANCE; TREATMENT OUTCOME; TREATMENT RESPONSE; COCAINE-RELATED DISORDERS; GENETIC POLYMORPHISM; GENETICS; HETEROZYGOTE DETECTION; MIDDLE AGED; PSYCHOLOGY;

ADULT; CATECHOL O-METHYLTRANSFERASE; COCAINE; COCAINE-RELATED DISORDERS; COGNITIVE THERAPY; FEMALE; GENOTYPE; HETEROZYGOTE DETECTION; HUMANS; MALE; METHIONINE; MIDDLE AGED; POLYMORPHISM, GENETIC; THERAPY, COMPUTER-ASSISTED; TREATMENT OUTCOME; VALINE;

EID: 84937976889     PISSN: 10550496     EISSN: 15210391     Source Type: Journal    
DOI: 10.1111/ajad.12238     Document Type: Article

References (54)

1. Magill M, Ray LA,. Cognitive-behavioral treatment with adult alcohol and illicit drug users: a meta-analysis of randomized controlled trials. J Stud Alcohol drugs 2009; 70: 516-527.
2. Irvin JE, Bowers CA, Dunn ME, et al., Efficacy of relapse prevention: A meta-analytic review. J Consult Clin Psychol 1999; 67: 563-570.
3. Linden DE,. How psychotherapy changes the brain-the contribution of functional neuroimaging. Mol Psychiatr 2006; 11: 528-538.
4. Collerton D,. Psychotherapy and brain plasticity. Front Psychol 2013; 4: 548.
5. Joic- Begic N,. Cognitive behavioral therapy and neuroscience: Towards closer integration. Psychol Topics 2010; 19.
6. Goldapple M, Segal Z, Garson C, et al., Modulation of cortical-limbic pathways in major depression: Treatment specific effects of cognitive behavior therapy. Arch Gen Psychiatry 2004; 61.
7. Frewen PA, Dozois DJ, Lanius RA,. Neuroimaging studies of psychological interventions for mood and anxiety disorders: Empirical and methodological review. Clin Psychol Rev 2008; 28: 228-246.
8. Kandel ER,: A new intellectual framework for psychiatry. Am J Psychiatry 1998; 155: 457-469.
9. Butler AC, Chapman JE, Forman EM, et al., The empirical status of cognitive- behavioral therapy: A review of meta-analyses. Clin Psychol Rev 2006; 26: 17-31.
10. Tolin DF,: Is cognitive-behavioral therapy more effective than other therapies? A meta-analytic review. Clin Psychol Rev 2010; 30: 710-720.
11. Siegle GJ, Ghinassi F, Thase ME,. Neurobehavioral therapies in the 21st century: Summary of an emerging field and an extended example of cognitive control training for depression. Cogn Ther Res 2007; 31: 235-262.
12. Hollon SD,. Does cognitive therapy have an enduring effect? Cogn Ther Res 2003; 27: 71-75.
13. Carroll KM, Rounsaville BJ, Nich C, et al., One-year follow-up of psychotherapy and pharmacotherapy for cocaine dependence. Delayed emergence of psychotherapy effects. Arch Gen Psychiatry 1994; 51: 989-997.
14. DeRubeis RJ, Siegle GJ, Hollon SD,. Cognitive therapy versus medication for depression: Treatment outcomes and neural mechanisms. Nat Rev Neurosci 2008; 9: 788-796.
15. Kiluk BD, Nich C, Babuscio T, et al., Quality versus quantity: Acquisition of coping skills following computerized cognitive- behavioral therapy for substance use disorders. Addiction 2010; 105: 2120-2127.
16. Porto PR, Oliveira L, Mari J, et al., Does cognitive behavioral therapy change the brain? A systematic review of neuroimaging in anxiety disorders. J Neuropsychiatry Clin Neurosci 2009; 21: 114-125.
17. Roffman JL, Marci CD, Glick DM, et al., Neuroimaging and the functional neuroanatomy of psychotherapy. Psychol Med 2005; 35: 1385-1398.
18. Potenza MN, Sofuoglu M, Carroll KM, et al., Neuroscience of behavioral and pharmacological treatments for addictions. Neuron 2011; 69: 695-712.
19. Kumari V, Antonova E, Fannon D, et al., Beyond dopamine: Functional MRI predictors of responsiveness to cognitive behaviour therapy for psychosis. Front Behav Neurosci 2010; 4: 4.
20. McMahon FJ, Insel TR,. Pharmacogenomics and personalized medicine in neuropsychiatry. Neuron 2012; 74: 773-776.
21. Ando J, Ono Y, Wright MJ,. Genetic structure of spatial and verbal working memory. Behav Genet 2001; 31: 615-624.
22. Friedman NP, Miyake A, Young SE, et al., Individual differences in executive functions are almost entirely genetic in origin. J Exp Psychol Gen 2008; 137: 201-225.
23. Egan MF, Goldberg TE, Kolachana BS, et al., Effect of COMT Val108/158 Met genotype on frontal lobe function and risk for schizophrenia. Proc Natl Acad Sci USA 2001; 98: 6917-6922.
24. Carboni E, Tanda GL, Frau R, et al., Blockade of the noradrenaline carrier increases extracellular dopamine concentrations in the prefrontal cortex: Evidence that dopamine is taken up in vivo by noradrenergic terminals. J Neurochem 1990; 55: 1067-1070.
25. Malhotra AK, Kestler LJ, Mazzanti C, et al., A functional polymorphism in the COMT gene and performance on a test of prefrontal cognition. Am J Psychiatry 2002; 159: 652-654.
26. Rosa A, Peralta V, Cuesta MJ, et al., New evidence of association between COMT gene and prefrontal neurocognitive function in healthy individuals from sibling pairs discordant for psychosis. Am J Psychiatry 2004; 161: 1110-1112.
27. Congdon E, Constable RT, Lesch KP, et al., Influence of SLC6A3 and COMT variation on neural activation during response inhibition. Biol Psychol 2009; 81: 144-152.
28. Carpenter KM, Schreiber E, Church S, et al., Drug Stroop performance: Relationships with primary substance of use and treatment outcome in a drug-dependent outpatient sample. Addict Behav 2006; 31: 174-181.
29. Witte AV, Floel A,. Effects of COMT polymorphisms on brain function and behavior in health and disease. Brain Res bullet 2012; 88: 418-428.
30. Lonsdorf TB, Ruck C, Bergstrom J, et al., The COMTval158met polymorphism is associated with symptom relief during exposure-based cognitive-behavioral treatment in panic disorder. BMC Psychiatry 2010; 10: 99.
31. Beevers CG, McGeary JE,. Therapygenetics: Moving towards personalized psychotherapy treatment. Trends Cogn Sci 2012; 16: 11-12.
32. Andersson E, Ruck C, Lavebratt C, et al., Genetic polymorphisms in monoamine systems and outcome of cognitive behavior therapy for social anxiety disorder. PloS ONE 2013; 8: e79015.
33. Lester KJ, Hudson JL, Tropeano M, et al., Neurotrophic gene polymorphisms and response to psychological therapy. Transl Psychiatry 2012; 2: e108.
34. Eley TC, Hudson JL, Creswell C, et al., Therapygenetics: The 5HTTLPR and response to psychological therapy. Mol Psychiatry 2012; 17: 236-237.
35. Bockting CL, Mocking RJ, Lok A, et al., Therapygenetics: The 5HTTLPR as a biomarker for response to psychological therapy? Mol Psychiatry 2013; 18: 744-745.
36. Bryant RA, Felmingham KL, Falconer EM, et al., Preliminary evidence of the short allele of the serotonin transporter gene predicting poor response to cognitive behavior therapy in posttraumatic stress disorder. Biol Psychiatry 2010; 67: 1217-1219.
37. Hedman E, Andersson E, Ljotsson B, et al., Clinical and genetic outcome determinants of Internet- and group-based cognitive behavior therapy for social anxiety disorder. Acta psychiatr Scand 2012; 126: 126-136.
38. Greist JH,: A promising debut for computerized therapies. Am J Psychiat 2008; 165: 793-795.
39. Marks IM, Cavanagh K, Gega L,. Hands On Help: Computer-Aided Psychotherapy. Hove, UK: Psychol. Press; 2007.
40. Carroll KM, Ball SA, Martino S, et al., Computer-assisted cognitive- behavioral therapy for addiction. A randomized clinical trial of 'CBT4CBT'. Am J Psychiat 2008; 165: 881-888. PMCID: PMC2562873.
41. Carroll KM, Ball SA, Martino S, et al., Enduring effects of a computer- assisted training program for cognitive-behavioral therapy: A six-month follow-up of CBT4CBT. Drug Alcohol Depend 2009; 100: 178-181. PMCID: PMC2742309.
42. Carroll KM, Kiluk BD, Nich C, et al., Computer-assisted delivery of cognitive-behavioral therapy: Efficacy and durability of CBT4CBT among cocaine-dependent individuals maintained on methadone. Am J Psychiatry 2014; 171: 436-444.
43. Tammimaki AE, Mannisto PT,. Are genetic variants of COMT associated with addiction?. Pharmacogenet Genomics 2010; 20: 717-741.
44. Lohoff FW, Weller AE, Bloch PJ, et al., Association between the catechol-O- methyltransferase Val158Met polymorphism and cocaine dependence. Neuropsychopharmacology: Official Pub Am Coll Neuropsychopharmacology 2008; 33: 3078-3084.
45. Asmaro D, Carolan PL, Liotti M,. Electrophysiological evidence of early attentional bias to drug-related pictures in chronic cannabis users. Addict Behav 2014; 39: 114-121.
46. Munafo MR, Johnstone EC, Guo B, et al., Association of COMT Val108/158Met genotype with smoking cessation. Pharmacogenet Genomics 2008; 18: 121-128.
47. Cox WM, Fadardi JS, Pothos EM,. The Addiction-Stroop Test: Theoretical considerations and procedural recommendations. Psychol Bullet 2006; 132: 443-476.
48. Stout RL, Wirtz PW, Carbonari JP, et al., Ensuring balanced distribution of prognostic factors in treatment outcome research. J Stud Alcohol Suppl 1994; 12: 70-75.
49. First MB, Spitzer RL, Gibbon M, et al., Structured Clinical Interview for DSM-IV, Patient Edition. Washington, D.C.: American Psychiatric Press; 1995.
50. Robinson SM, Sobell LC, Sobell MB, et al., Reliability of the timeline followback for cocaine, cannabis, and cigarette use. Psychol Addict Behav: J Soc Psychol Addict Behav 2012. 28: 154-162
51. Waters AJ, Sayette MA, Franken IH,. Generalizability of carry-over effects in the emotional Stroop task. Behav Res Therapy 2005; 43: 715-732.
52. Bolla K, Ernst M, Kiehl K, et al., Prefrontal cortical dysfunction in abstinent cocaine abusers. J Neuropsychiatr Clin Neurosci 2004; 16: 456-464.
53. Carroll KM, Kiluk BD, Nich C, et al., Toward empirical identification of a clinically meaningful indicator of treatment outcome: Features of candidate indicators and evaluation of sensitivity to treatment effects and relationship to one year follow up cocaine use outcomes. Drug Alcohol Depen 2014; 137: 3-19.
54. Higgins ST, Wong CJ, Badger GJ, et al., Contingent reinforcement increases cocaine abstinence during outpatient treatment and one year follow-up. J Consult Clin Psychol 2000; 68: 64-72.